Helicobacter pylori infection and small intestinal bacterial overgrowth: a systematic review and meta-analysis

BMC Microbiology

Table 1 Characteristics of the included studies

Study	Design	Country	Diagnosis	Sample size	Mean age (years)	Men (%)	HP evaluation	HP positive	SIBO evaluation	SIBO positive
Fasano 2013	CS	Italy	PD patients without GI disease, no exposure to PPI or antibiotics	33	68.1	58.1	UBT	11	LBT	18
Gravina 2015a	CS	Italy	Patients with rosacea, no exposure to PPI or antibiotics	90	51.5	43.3	UBT	44	GBT	9
Gravina 2015b	CS	Italy	Patients with skin naevi, no exposure to PPI or antibiotics	90	48	47.8	UBT	24	GBT	7
Del Zompo 2016	CS	Italy	Patients with GI symptoms, no exposure to PPI or antibiotics	136	42.5	30.1	UBT	36	LBT	17
Enko 2017	CS	Austria	Patients with GI symptoms, no exposure to PPI or antibiotics	109	44	33	UBT	36	GBT	35
Mujeeb 2019	CS	India	Patients with GI symptoms undergoing UGIE, no exposure to antibiotics	80	45.4	75.2	UBT	28	QDC	19
Radionova 2020a	CS	Ukraine	Diabetic patients with chronic active gastritis, no exposure to antibiotics	92	61.6	68.5	SAgT	71	GBT	69
Radionova 2020b	CS	Ukraine	Non-diabetic patients with chronic active gastritis, no exposure to antibiotics	80	54	57.5	SAgT	48	GBT	33
Kim 2022	CS	Korea	Patients with GI symptoms undergoing UGIE, no exposure to PPI or antibiotics	62	49.8	30.6	RUT	22	GBT	11
Zhu 2022	CS	China	Patients with GI symptoms, no exposure to PPI or antibiotics	102	42.1	48	UBT	53	GBT	47

HP: helicobacter pylori; SIBO: small intestinal bacterial overgrowth; GI: gastrointestinal; PD: Parkinson’s disease; PPI: pronto pump inhibitor; UGIE: upper gastrointestinal endoscopy; UBT: urea breath test; SAgT: stool antigen test; RUT: rapid urease test; LBT: lactulose breath test; QDC: quantitative duodenal aspirate culture; GBT: glucose breath test;

ISSN: 1471-2180